CLINICAL TRIALS PROFILE FOR METADATE CD
✉ Email this page to a colleague
All Clinical Trials for METADATE CD
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00301639 ↗ | A PET Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy Of Two Long-Acting Formulations of Methylphenidate in Adults | Completed | McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. | Phase 3 | 2005-03-01 | The specific aim of this study is to document the pharmacokinetics of dopamine transporter DAT receptor occupancy of OROS MPH and Metadate CD using PET scanning with C-11 Altropane as the ligand. We hypothesize that CNS DAT occupancy of OROS MPH will be greater than that of Metadate CD at 10 hours after administration. |
| NCT00301639 ↗ | A PET Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy Of Two Long-Acting Formulations of Methylphenidate in Adults | Completed | Massachusetts General Hospital | Phase 3 | 2005-03-01 | The specific aim of this study is to document the pharmacokinetics of dopamine transporter DAT receptor occupancy of OROS MPH and Metadate CD using PET scanning with C-11 Altropane as the ligand. We hypothesize that CNS DAT occupancy of OROS MPH will be greater than that of Metadate CD at 10 hours after administration. |
| NCT00381758 ↗ | The COMACS Study: A Comparison of Methylphenidates in an Analog Classroom Setting | Completed | UCB Pharma | Phase 4 | 2002-05-01 | This study was designed to compare Concerta Extended Release tablets with Metadate CD capsules in children with ADHD who were between 6 and 12 years old. The effects on ADHD symptoms, and any side effects of treatment, were measured for 12 hours after dosing in a simulated classroom. The treatments were blinded and the effects were compared with a Placebo. |
| NCT01100658 ↗ | Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors | Terminated | Children's Cancer Research Fund United States | N/A | 2010-05-01 | While neurocognitive impairments in attention, memory and executive functioning are commonly reported sequelae of childhood leukemia and brain tumors, studies have only recently begun to examine the treatment of attention deficits in this population. Numerous studies have examined the effectiveness of methylphenidate in the treatment of children with attention deficit hyperactivity disorder (ADHD). However, the effectiveness of this medication for improving attention and behavioral functioning in children with medical illnesses or brain injury are less clear. Patients will be randomized to receive one week of Metadate CD (a controlled release form of methylphenidate, similar to Ritalin) and one week of placebo in a double-blind fashion. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for METADATE CD
Condition Name
Clinical Trial Locations for METADATE CD
Trials by Country
Clinical Trial Progress for METADATE CD
Clinical Trial Phase
Clinical Trial Sponsors for METADATE CD
Sponsor Name
